ASIA-PACIFIC CONTINUOUS GLUCOSE MONITORING MARKET - GROWTH, TRENDS, COVID-19 IMPACT, AND FORECASTS (2022 - 2027)

The Asia-Pacific Continuous Glucose Monitoring Market is segmented by Component (Sensors, Durables), and Geography.

Market Snapshot

Asia-Pacific Continuous Glucose Monitoring Market Overview
Study Period: 2016-2027
Base Year: 2021
CAGR: >16 %

Need a report that reflects how COVID-19 has impacted this market and its growth?

Market Overview

The Asia-Pacific continuous glucose monitoring market is expected to register a CAGR of more than 16% during the forecast period. The countries in Asia-Pacific have a high prevalence of diabetes. According to IDF, in 2019, approximately 2 million deaths were attributed directly to diabetes in Asia-Pacific. An additional 1.2 million deaths were caused due to high blood glucose, in 2019. The countries in the Asia-Pacific region account for close to 61% of the total diabetic population in the world in the year 2020, since the prevalence of diabetes in these countries is consistently showing increasing trends.

Scope of the Report

The study provides a detailed analysis of the CGM market in Asia-Pacific, including market share, market size, forecast, and industry review.

By Product
By Component (Value and Volume, 2016 - 2026)
Continuous Glucose Monitoring
Sensors
Durables
By Geography (Value and Volume, 2016 - 2026)
Asia-Pacific
Australia
By Component (Sensors and Durables)
China
By Component (Sensors and Durables)
India
By Component (Sensors and Durables)
Indonesia
By Component (Sensors and Durables)
Japan
By Component (Sensors and Durables)
Malaysia
By Component (Sensors and Durables)
Philippines
By Component (Sensors and Durables)
South Korea
By Component (Sensors and Durables)
Thailand
By Component (Sensors and Durables)
Vietnam
By Component (Sensors and Durables)
Rest of Asia-Pacific
By Component (Sensors and Durables)

Report scope can be customized per your requirements. Click here.

Key Market Trends

CGMs Prove to Be an Instrumental Tool that May Help in Maintaining the Glycemic Balance

The prevalence among the adult population, aged between 20 and 70 years, is anticipated to rise from 285 million, in 2010, to a staggering 438 million by 2030. In patients relying on insulin pumps or multiple daily injection (MDI) therapy, the CGM proves to be an instrumental tool that helps in the improvement of glycemic balance without aggregating the danger for severe hypoglycemia. As studied in several clinical trials, diabetic patients with T1DM have been shown to have better glycemic control, as compared to when glucometer is used for routine self-monitoring blood glucose. The trend follows even in children who use CGM in a steady fashion. The results in these children show better-glycosylated hemoglobin (HbA1c) levels without an amplified frequency of hypoglycemia. The current, approved CGM models administer glucose oxidase-based electrochemical subcutaneous sensors for the detection of glucose levels in interstitial fluid.

Revenue

China Held the Highest Market Share in the Asia-Pacific Continuous Glucose Monitoring Market in 2020

In the Asia-Pacific continuous glucose monitoring market, China accounted for close to 38% of the market share in 2020. China registered more than 30,000 new Type-1 cases in 2020. As CGM is mostly used by Type-1 diabetes patients, it is estimated that the CGM market in China will reach USD 62 million by the end of 2026. Japan held the second-highest market share in 2020, and it is expected to register a CAGR of about 15.46% during the forecast period. It is imperative that the CGM devices are used alongside insulin pumps, and as the trends show a higher number of diabetic patients using insulin pumps for diabetes management, it can be predicted that the number of units of CGM devices sold may also follow.

Country

Competitive Landscape

The Asia-Pacific continuous glucose monitoring market is highly consolidated. Dexcom, Medtronic, and Abbott held more than 60% of the market share in 2020. Some of the recent developments in the market were: In February 2019, Terumo Corporation, a Tokyo-based company, announced its plans to sell the Dexcom G4 PLATINUM Continuous Glucose Monitoring System in Japan.

RECENT DEVELOPMENTS

In July 2021, Terumo Corporation announced the launch of the Dexcom G6 continuous glucose monitoring (CGM) system in Japan. U.S.-based Dexcom manufactures the Dexcom product, and Terumo holds the exclusive distribution agreement of Dexcom Products in Japan.

In January 2021, the National Diabetes Services Scheme (NDSS) Australia approved to use of Dexcom G6 CGM device through the NDSS Subsidy Initiative, if diabetes patients are using a Tandem t: slim X2 insulin pump and meet the NDSS criteria.

Table of Contents

  1. 1. INTRODUCTION

    1. 1.1 Study Assumptions

    2. 1.2 Scope of the Study

  2. 2. RESEARCH METHODOLOGY

  3. 3. EXECUTIVE SUMMARY

  4. 4. MARKET DYNAMICS

    1. 4.1 Market Overview

    2. 4.2 Market Drivers

    3. 4.3 Market Restraints

    4. 4.4 Porter's Five Forces Analysis

      1. 4.4.1 Bargaining Power of Suppliers

      2. 4.4.2 Bargaining Power of Consumers

      3. 4.4.3 Threat of New Entrants

      4. 4.4.4 Threat of Substitute Products and Services

      5. 4.4.5 Intensity of Competitive Rivalry

  5. 5. MARKET SEGMENTATION

    1. 5.1 By Product

      1. 5.1.1 By Component (Value and Volume, 2016 - 2026)

        1. 5.1.1.1 Continuous Glucose Monitoring

          1. 5.1.1.1.1 Sensors

          2. 5.1.1.1.2 Durables

    2. 5.2 By Geography (Value and Volume, 2016 - 2026)

      1. 5.2.1 Asia-Pacific

        1. 5.2.1.1 Australia

          1. 5.2.1.1.1 By Component (Sensors and Durables)

        2. 5.2.1.2 China

          1. 5.2.1.2.1 By Component (Sensors and Durables)

        3. 5.2.1.3 India

          1. 5.2.1.3.1 By Component (Sensors and Durables)

        4. 5.2.1.4 Indonesia

          1. 5.2.1.4.1 By Component (Sensors and Durables)

        5. 5.2.1.5 Japan

          1. 5.2.1.5.1 By Component (Sensors and Durables)

        6. 5.2.1.6 Malaysia

          1. 5.2.1.6.1 By Component (Sensors and Durables)

        7. 5.2.1.7 Philippines

          1. 5.2.1.7.1 By Component (Sensors and Durables)

        8. 5.2.1.8 South Korea

          1. 5.2.1.8.1 By Component (Sensors and Durables)

        9. 5.2.1.9 Thailand

          1. 5.2.1.9.1 By Component (Sensors and Durables)

        10. 5.2.1.10 Vietnam

          1. 5.2.1.10.1 By Component (Sensors and Durables)

        11. 5.2.1.11 Rest of Asia-Pacific

          1. 5.2.1.11.1 By Component (Sensors and Durables)

  6. 6. MARKET INDICATORS

    1. 6.1 Type-1 Diabetes Population (2016 - 2026)

    2. 6.2 Type-2 Diabetes Population (2016 - 2026)

  7. 7. COMPETITIVE LANDSCAPE

    1. 7.1 Company Profiles

      1. 7.1.1 Abbott

      2. 7.1.2 Dexcom

      3. 7.1.3 Medtronics

      4. 7.1.4 Senseonics

  8. 8. MARKET OPPORTUNITIES AND FUTURE TRENDS

You can also purchase parts of this report. Do you want to check out a section wise price list?

Frequently Asked Questions

The Asia-Pacific Continuous Glucose Monitoring Market market is studied from 2016 - 2026.

The Asia-Pacific Continuous Glucose Monitoring Market is growing at a CAGR of >16% over the next 5 years.

The Asia-Pacific Continuous Glucose Monitoring Market is valued at 648 Million USD in 2016.

The Asia-Pacific Continuous Glucose Monitoring Market is valued at 1730 Million USD in 2026.

Dexcom, Medtronic, Abbott, Senseonics are the major companies operating in Asia-Pacific Continuous Glucose Monitoring Market.

80% of our clients seek made-to-order reports. How do you want us to tailor yours?

Please enter a valid email id!

Please enter a valid message!